ARQT ARCUTIS BIOTHERAPEUTICS, INC.
Research report · from SEC EDGAR · close 2026-07-14
$26.81 -1.1%
$3.35B mkt cap
executive summary
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) is a $3.35B company. Revenue is $372.1M (+123.4% y/y) at a -4% net margin. It is not yet profitable. Our health score is B (73/100). 1 red flag on file. Smart money is buying (1 Congress). It funds itself; low dilution risk.
Revenue (FY)
$372.1M
+123.4% y/y
⚠One-sided insider selling
16 insider sales and no open-market buys in the recent window.
who's buying
Insider buys / sells
0 / 16
Cash & ST investments
$34.8M
Operating cash flow
-$5.6M
Dilution shelf
active shelf
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices — every figure is real and sourced; nothing is fabricated or predicted. Filings lag 40–90 days. Educational, not investment advice. Generated 2026-07-14 by stocktools.ai.